| Sheena Neys, | |
|
207 2nd Ave Se, Jamestown, ND 58401-4272 | |
| (701) 252-3376 | |
| Not Available |
| Full Name | Sheena Neys |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 207 2nd Ave Se, Jamestown, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780016592 | NPI | - | NPPES |
| 1029 | Other | ND | LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1029 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sheena Neys, 207 2nd Ave Se, Jamestown, ND 58401-4272 Ph: (701) 252-3376 | Sheena Neys, 207 2nd Ave Se, Jamestown, ND 58401-4272 Ph: (701) 252-3376 |
News Archive
Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. The results, which are presented in Nature, may provide future treatments of intestinal diseases and obesity.
Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.
Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.
About 50,000 Danish diabetic patients are treated with GLP-1-based medicine. GLP-1 is a hormone that reduces the blood sugar and inhibits the appetite, and it is a frequent treatment for type 2 diabetes and obesity.
Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
› Verified 2 days ago
Laurie Anne Schauer, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 701 3rd St Nw, Jamestown, ND 58401 Phone: 701-252-3850 Fax: 701-952-5154 | |
Adeline Eamon, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 701 3rd St Nw, Jamestown, ND 58401 Phone: 701-568-5175 | |
Lori Dawn Love, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 701 3rd St Nw, Jamestown, ND 58401 Phone: 701-252-3850 Fax: 701-952-5154 | |
Stephanie Joy Nelson, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 701 3rd St Nw, Jamestown, ND 58401 Phone: 701-252-3850 Fax: 701-952-5154 | |
James Harold George Bergman, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 701 3rd St Nw, Jamestown, ND 58401 Phone: 701-252-3850 | |
Ashley Ann Boom, MA, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 102 2nd Ave Sw, Jamestown, ND 58401 Phone: 701-252-6066 | |
Andy Kolff, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 207 2nd Ave Se, Jamestown, ND 58401 Phone: 701-252-3376 |